missing translation for 'onlineSavingsMsg'
Learn More

Invitrogen™ Daclizumab Recombinant Monoclonal Antibody
GREENER_CHOICE

Recombinant Monoclonal Antibody

£397.00 - £1002.00

Specifications

Antigen Daclizumab Humanized
Concentration 1 mg/mL
Content And Storage -20°C, Avoid Freeze/Thaw Cycles
Applications ELISA, Flow Cytometry, Functional Assay, Surface Plasmon Resonance
Classification Recombinant Monoclonal
View More Specs

Products 2
Product Code Brand Quantity Price Quantity & Availability  
Product Code Brand Quantity Price Quantity & Availability  
30283004
GREENER_CHOICE
View Documents
Invitrogen™
MA558663
100 μg
£397.00
100µg
View alternative products
Save Up to 
»
Please to purchase this item. Need a web account? Register with us today!
30283917
View Documents
Invitrogen™
MA558664
1 mg
£1002.00
1mg
View alternative products
Save Up to 
»
Please to purchase this item. Need a web account? Register with us today!
Description

Description

For reconstitution, add sterile, distilled water to achieve a final antibody concentration of 1 mg/mL. Gently shake to solubilize the protein completely. Do not vortex. Reconstituted products should be stored at -80 °.

Humanized IgG1 Mab that binds to the human interleukin-2 receptor (anti-Tac or anti-CD25). Daclizumab is a composite of human (90%) and murine (10%) antibody sequences. The human sequences were derived from the constant domains of human IgG1 and the variable framework regions of the Eu myeloma antibody. The murine sequences were derived from the complementarity-determining regions of a murine anti-Tac antibody. On 22 April 2008, Roche Registration Limited chose to voluntarily withdraw the marketing authorization for their product Zenapax (daclizumab), as indicated for the prophylaxis of acute organ rejection in de novo allogeneic renal transplantation and used concomitantly with an immunosuppressive regimen like cyclosporine and corticosteroids in patients who are not immunized, for commercial reasons and confirmed that this decision was not related to any safety concerns associated with the use of Zenapax (daclizumab) 2. Regardless of the withdrawal of Zenapax, Biogen and Abbvie's Zinbryta (daclizumab), as indicated for the treatment of adult patients with relapsing forms of multiple sclerosis, was approved for use by the FDA in 2016.
Specifications

Specifications

Daclizumab Humanized
-20°C, Avoid Freeze/Thaw Cycles
Recombinant Monoclonal
Lyophilized
IgG1
Human
BIIB019; DAC HYP
Antibody
1 mg/mL
ELISA, Flow Cytometry, Functional Assay, Surface Plasmon Resonance
Unconjugated
Human
RUO
25mM histidine with 8% sucrose, 0.01% Tween 80 and no preservative; pH 6.2
Primary
Protein A
Videos
SDS
Documents

Documents

Product Certifications
Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Thank You! Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.